Literature DB >> 27930322

Casitas B-cell lymphoma (Cbl) proteins protect mammary epithelial cells from proteotoxicity of active c-Src accumulation.

Chandrani Mukhopadhyay1, Aleata Triplett1, Tom Bargar2, Carol Heckman3, Kay-Uwe Wagner1,4, Mayumi Naramura5,2,4.   

Abstract

Casitas B-cell lymphoma (Cbl) family ubiquitin ligases negatively regulate tyrosine kinase-dependent signal transduction by promoting degradation of active kinases. We and others previously reported that loss of Cbl functions caused hyperproliferation in lymphoid and hematopoietic systems. Unexpectedly, Cbl deletion in Cbl-b-null, Cbl-c-null primary mouse mammary epithelial cells (MECs) (Cbl triple-deficiency) induced rapid cell death despite enhanced MAP kinase and AKT activation. Acute Cbl triple-deficiency elicited distinct transcriptional and biochemical responses with partial overlap with previously described cellular reactions to unfolded proteins and oxidative stress. Although the levels of reactive oxygen species were comparable, detergent-insoluble protein aggregates containing phosphorylated c-Src accumulated in Cbl triple-deficient MECs. Treatment with a broad-spectrum kinase inhibitor dasatinib blocked protein aggregate accumulation and restored in vitro organoid formation. This effect is most likely mediated through c-Src because Cbl triple-deficient MECs were able to form organoids upon shRNA-mediated c-Src knockdown. Taking these data together, the present study demonstrates that Cbl family proteins are required to protect MECs from proteotoxic stress-induced cell death by promoting turnover of active c-Src.

Entities:  

Keywords:  CBL; protein degradation; stress response; tyrosine kinase; ubiquitin ligase

Mesh:

Substances:

Year:  2016        PMID: 27930322      PMCID: PMC5187741          DOI: 10.1073/pnas.1615677113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

1.  Autophagic targeting of Src promotes cancer cell survival following reduced FAK signalling.

Authors:  Emma Sandilands; Bryan Serrels; David G McEwan; Jennifer P Morton; Juan Pablo Macagno; Kenneth McLeod; Craig Stevens; Valerie G Brunton; Wallace Y Langdon; Marcos Vidal; Owen J Sansom; Ivan Dikic; Simon Wilkinson; Margaret C Frame
Journal:  Nat Cell Biol       Date:  2011-12-04       Impact factor: 28.824

2.  Restoration of p53 function leads to tumour regression in vivo.

Authors:  Andrea Ventura; David G Kirsch; Margaret E McLaughlin; David A Tuveson; Jan Grimm; Laura Lintault; Jamie Newman; Elizabeth E Reczek; Ralph Weissleder; Tyler Jacks
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

3.  Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer.

Authors:  Bryan E Welm; Gerrit J P Dijkgraaf; Anita S Bledau; Alana L Welm; Zena Werb
Journal:  Cell Stem Cell       Date:  2008-01-10       Impact factor: 24.633

Review 4.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

5.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

6.  Measuring ER stress and the unfolded protein response using mammalian tissue culture system.

Authors:  Christine M Oslowski; Fumihiko Urano
Journal:  Methods Enzymol       Date:  2011       Impact factor: 1.600

7.  Autoinhibition and phosphorylation-induced activation mechanisms of human cancer and autoimmune disease-related E3 protein Cbl-b.

Authors:  Yoshihiro Kobashigawa; Akira Tomitaka; Hiroyuki Kumeta; Nobuo N Noda; Masaya Yamaguchi; Fuyuhiko Inagaki
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-07       Impact factor: 11.205

Review 8.  Endocytosis and intracellular trafficking of ErbBs.

Authors:  Alexander Sorkin; Lai Kuan Goh
Journal:  Exp Cell Res       Date:  2008-08-28       Impact factor: 3.905

9.  Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.

Authors:  Johanna M Duyvestyn; Samuel J Taylor; Samantha A Dagger; Marlene Orandle; Herbert C Morse; Christine B F Thien; Wallace Y Langdon
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

Review 10.  EGF receptor trafficking: consequences for signaling and cancer.

Authors:  Alejandra Tomas; Clare E Futter; Emily R Eden
Journal:  Trends Cell Biol       Date:  2013-11-29       Impact factor: 20.808

View more
  4 in total

1.  An Mtb-Human Protein-Protein Interaction Map Identifies a Switch between Host Antiviral and Antibacterial Responses.

Authors:  Bennett H Penn; Zoe Netter; Jeffrey R Johnson; John Von Dollen; Gwendolyn M Jang; Tasha Johnson; Yamini M Ohol; Cyrus Maher; Samantha L Bell; Kristina Geiger; Guillaume Golovkine; Xiaotang Du; Alex Choi; Trevor Parry; Bhopal C Mohapatra; Matthew D Storck; Hamid Band; Chen Chen; Stefanie Jäger; Michael Shales; Dan A Portnoy; Ryan Hernandez; Laurent Coscoy; Jeffery S Cox; Nevan J Krogan
Journal:  Mol Cell       Date:  2018-08-16       Impact factor: 17.970

Review 2.  c-Cbl: An Important Regulator and a Target in Angiogenesis and Tumorigenesis.

Authors:  Chimera L Lyle; Mostafa Belghasem; Vipul C Chitalia
Journal:  Cells       Date:  2019-05-23       Impact factor: 6.600

3.  G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer.

Authors:  Chandrani Mukhopadhyay; Chenyi Yang; Limei Xu; Deli Liu; Yu Wang; Dennis Huang; Lesa Dayal Deonarine; Joanna Cyrta; Elai Davicioni; Andrea Sboner; Brian D Robinson; Arul M Chinnaiyan; Mark A Rubin; Christopher E Barbieri; Pengbo Zhou
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

4.  Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma.

Authors:  Peng Li; Hongliang Liu; Zhiqiang Zhang; Xiaodong Lv; Huijuan Wang; Jie Ma; Zhiyong Ma; Xiujuan Qu; Yue-E Teng
Journal:  Med Sci Monit       Date:  2018-01-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.